I5X Stock Overview
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.34 |
| 52 Week High | US$1.67 |
| 52 Week Low | US$0.82 |
| Beta | 1.77 |
| 1 Month Change | 1.44% |
| 3 Month Change | 3.80% |
| 1 Year Change | 27.52% |
| 3 Year Change | -78.91% |
| 5 Year Change | -65.40% |
| Change since IPO | -91.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| I5X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.6% | 1.8% | 1.1% |
| 1Y | 27.5% | -23.5% | 1.9% |
Return vs Industry: I5X exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: I5X exceeded the German Market which returned 2% over the past year.
Price Volatility
| I5X volatility | |
|---|---|
| I5X Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I5X has not had significant price volatility in the past 3 months.
Volatility Over Time: I5X's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
| I5X fundamental statistics | |
|---|---|
| Market cap | €327.36m |
| Earnings (TTM) | -€89.45m |
| Revenue (TTM) | €5.81m |
56.0x
P/S Ratio-3.6x
P/E RatioIs I5X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I5X income statement (TTM) | |
|---|---|
| Revenue | US$6.23m |
| Cost of Revenue | US$54.73m |
| Gross Profit | -US$48.51m |
| Other Expenses | US$47.40m |
| Earnings | -US$95.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | -779.25% |
| Net Profit Margin | -1,540.63% |
| Debt/Equity Ratio | 0% |
How did I5X perform over the long term?
See historical performance and comparison